These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1149754)

  • 61. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 63. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 65. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 66. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 67. [Respiratory functions in parkinsonian patients with predominant akinesia during treatment with decarboxylase-blocked L-dopa (author's transl)].
    Oppel F; Hüttemann U
    Dtsch Med Wochenschr; 1975 Jul; 100(27):1461-4. PubMed ID: 1132357
    [TBL] [Abstract][Full Text] [Related]  

  • 68. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
    Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism].
    Katsuki T; Shimizu N; Mizuno Y
    No To Shinkei; 1984 Dec; 36(12):1201-5. PubMed ID: 6529518
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 74. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Combined (surgical and drug) therapy of parkinsonism].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism.
    Tohgi H; Takahashi S; Abe T; Utsugisawa K
    Eur Neurol; 2001; 46(1):1-10. PubMed ID: 11455176
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
    Melamed E; Bitton V; Zelig O
    Clin Neuropharmacol; 1986; 9(2):182-8. PubMed ID: 3085928
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The "off-on" phenomenon during treatment of parkinson's disease with levodopa (author's transl)].
    Wajsbort J
    J Neurol; 1977 Apr; 215(1):59-66. PubMed ID: 67200
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical pharmacokinetics of levodopa in parkinson's disease.
    Bianchine JR; Shaw GM
    Clin Pharmacokinet; 1976; 1(5):313-38. PubMed ID: 797502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.